↓ Skip to main content

Burden of herpes zoster and post-herpetic neuralgia in Sweden

Overview of attention for article published in BMC Infectious Diseases, May 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
2 X users
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Burden of herpes zoster and post-herpetic neuralgia in Sweden
Published in
BMC Infectious Diseases, May 2015
DOI 10.1186/s12879-015-0951-7
Pubmed ID
Authors

Jonas Nilsson, Tobias Cassel, Lars Lindquist

Abstract

The societal economic burden of herpes zoster in Sweden is not well described today. This study is a top-down analysis of Swedish registers with the objective to describe the burden of herpes zoster and post-herpetic neuralgia in Sweden during 2011. Data for inpatient care; outpatient primary and specialized cares; the prescriptions of drugs, sick leave and the number or diagnostic tests were collected from Swedish national databases. The incidence of the disease was estimated based on the number of prescriptions of antiviral drugs. The incidence of herpes zoster was estimated to 315 and 577 cases per 100,000 people for patients at all ages and > = 50 years, respectively. Almost 30,000 patients at all ages were diagnosed with herpes zoster and the societal cost to treat these patients, including the cost to treat those patients who later developed post-herpetic neuralgia, added up to nearly 227 MSEK (31.6 M€) which corresponds to 7,600 SEK (€870) per patient. The main contributors to the total cost for the treatment of HZ patients were primary care (43 %); sick leave (28 %); hospitalization (10 %) and specialist care (7 %). Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M€) to the overall costs for patients at all ages. The corresponding total cost including only patients 50 years and older was 168 MSEK (19.2 M€) or 8,200 SEK (€939) per patient. The current study demonstrates that the burden of herpes zoster is significant in Sweden. The society, the health care payers and the patients potentially have a lot to gain by introducing a vaccination program to patients 50 years and older and as a consequence reduce the economic and clinical burden of herpes zoster and post-herpetic neuralgia.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 22%
Student > Ph. D. Student 5 12%
Researcher 4 10%
Student > Bachelor 3 7%
Student > Doctoral Student 3 7%
Other 7 17%
Unknown 10 24%
Readers by discipline Count As %
Medicine and Dentistry 13 32%
Economics, Econometrics and Finance 3 7%
Agricultural and Biological Sciences 2 5%
Unspecified 2 5%
Social Sciences 2 5%
Other 6 15%
Unknown 13 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2022.
All research outputs
#6,608,166
of 23,775,451 outputs
Outputs from BMC Infectious Diseases
#2,042
of 7,911 outputs
Outputs of similar age
#76,082
of 269,066 outputs
Outputs of similar age from BMC Infectious Diseases
#17
of 79 outputs
Altmetric has tracked 23,775,451 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 7,911 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,066 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.